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Abstract 
Background: Chemotherapy induced peripheral neuropathy (CIPN) is a common, 
potentially reversible side-effect of some chemotherapeutic agents. CIPN is associated 
with decreased balance, function and quality of life (QoL). This association has to 
date been under-investigated. 
Aims:  
To profile patients presenting with CIPN using the modified Total Neuropathy Score 
(mTNS) in this cross-sectional study. 
To examine the relationship between CIPN (measured by mTNS) and indices of 
balance, quality of life (QoL) and function 
Methods: Patients receiving neurotoxic chemotherapy regimens were identified using 
hospital databases. Those who did not have a pre-existing neuropathy were invited to 
complete mTNS, berg balance scale (BBS), timed up and go (TUG), and FACT-G 
QoL questionnaire. mTNS scores were profiled and also correlated with BBS, TUG 
and FACT-G using Spearmans correlation coefficient.  
Results: A total of 29 patients undergoing neurotoxic chemotherapy regimens were 
tested. The patients mTNS scores ranged between 1 and 12 (median = 5), indicating 
that all patients had clinical evidence of neuropathy on mTNS. No significant 
correlations were found between mTNS and BERG (r = -.29), TUG (r = .14), or 
FACT-G (r = 0.05). 
Conclusions: This study found a high prevalence of CIPN in patients treated with 
neurotoxic chemotherapy regimens. The mTNS provided a clinically applicable, 
sensitive screening tool for CIPN which could prove useful in clinical practice. mTNS 
did not correlate with BBS, TUG or FACT-G in this sample, possibly due to relatively 
mild levels of CIPN and consequent subtle impairments which were not adequately 
captured by gross functional assessments.  
 
Keywords: Peripheral Neuropathy, Neurotoxic, Physiotherapy, Chemotherapy, 
Function 
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Introduction 
 
Peripheral neuropathy is a common, potentially reversible side-effect of some 
chemotherapeutic agents. Reversibility is dependant on early identification and 
modification of chemotherapy. Currently in clinical practice, general common toxicity 
scales are used to asses Chemotherapy Induced Peripheral Neuropathy (CIPN). 
However, these are heavily reliant on the patients subjective reports, and can be 
insensitive to change [1]. Studies suggest the incidence and sequalae of CIPN are 
poorly understood [2, 3] with more comprehensive investigation required [2, 4].  
 
Peripheral neuropathy is associated with decreased balance, function and 
quality of life (QoL) [5]. Despite much research in the area of diabetic neuropathy and 
function, the association between CIPN and function has to date been under-
investigated. Also, physiotherapy assessment and intervention in CIPN has not been 
extensively researched.  
 
Aims:  
1) To profile patients presenting with CIPN using the modified Total Neuropathy 
Score (mTNS) in this cross-sectional study [6]. 
 
2) To examine the relationship between CIPN (as measured by  mTNS) and 
indices of balance, QoL and Function 
 
Methods 
 
Patient Recruitment 
 
Included in the study were patients aged between 18 and 75 years of age who had 
completed ≥3 cycles of any of the following neurotoxic chemotherapy regimens: 
paclitaxel or docetaxel from the taxane class; vincristine or vinorelbine from the vinca 
alkaloid class; cisplatin, carboplatin or oxaliplatin from the platinum compounds 
class. Peripheral neuropathy can arise from metabolic, vascular, immunological or 
hereditary causes. For this reason any patients with previously diagnosed peripheral 
neuropathy were excluded from taking part in the study [7]. Other exclusion criteria 
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included any pre-existing neurological disorders, known diabetes, alcoholism, HIV, 
peripheral vascular disease, B12 deficiency, or inability to give informed consent. 
 
Patients were identified using the Beaumont Hospital pharmacy chemotherapy order 
lists. Once patients on neurotoxic regimens had been identified from these lists, their 
medical charts were screened by the principal investigator (lead author) for 
inclusion/exclusion criteria. Information leaflets were posted to a total of 37 patients 
who met these criteria. On arrival to the Day Oncology Ward for their chemotherapy 
treatment, these patients were approached and invited to participate in the study. A 
total of 29 patients agreed to take part. The patients gave written informed consent 
and were tested while awaiting their chemotherapy treatment to arrive from the 
pharmacy department. Patient assessments ranged in length from 20 – 30 minutes and 
were completed within a seven week period between July and August 2011. 
 
Ethical approval was sought from the Ethics Medical Research Committee at 
Beaumont Hospital and was granted on 24
th
 June 2011. 
 
Patient Measurement 
 
Instruments Employed 
Modified Total Neuropathy Score (mTNS) 
 
The Total Neuropathy Score (TNS) was first developed in 1994 [8]. Although it 
performed well in CIPN patients, it included nerve conduction studies, making it 
unsuitable for routine clinical use. Various authors have described versions of the 
TNS since then. In 2006 the mTNS, a version which did not include nerve conduction 
studies was first used [5]. This correlated well with the original TNS, indicating that 
nerve conduction studies did not add value to the test, and providing a clinically 
feasible alternative [5]. The mTNS is scored 0-24, with each neuropathy item being 
rated 0 to 4. A higher total score indicates a more severe neuropathy. 
 
When the first version of the TNS was developed in 1994 (a 0-21 scoring system), 
results scores were divided into 3 levels: 0-7, 8-14, and 15-21 for mild, moderate, and 
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severe neuropathy [8]. Applying this same system to the modern mTNS, the 3 
severity levels are: 0-8, 9-16, and 17-24. 
 
As guidelines for using the grading tools for peripheral neuropathy are poorly 
described [7], standardised clinical testing [9] was used for the following items of the 
mTNS: vibration sense (using a 128Hz tuning fork), pin level test (using a neurotip
TM
 
- Owen Mumford Ltd), and reflexes. 
  
Timed up and Go (TUG) 
 
The TUG has been shown to have high levels of validity [10] and reliability [11]. The 
standard protocol was used in completing the TUG score. Following a practice trial, 
each patient was timed to get up from the chair, walk three metres at their usual pace, 
turn around and walk back to sit down in the chair again. A chair of standard height, 
42”, was used each time for the test.  
 
Berg Balance Scale (BBS) 
 
The standard instructions were used in completing the BBS. A step of standard height, 
7”, was used each time for item 12 of the scale. The BBS is marked out of a total of 
fifty-six marks. A lower score indicates worse balance, with low falls risk being 
classified as 41-56, medium falls risk 21-40, and high falls risk 0-20. The BBS was 
chosen for its ease of use and because it has been shown to be a valid and reliable 
measure of balance [12]. 
 
Functional Assessment of Cancer Therapy-General (FACT-G)  
 
The FACT-G was originally developed exclusively for cancer patients but has now 
become widely used for many chronic illnesses [13]. It was chosen for this study due 
to its well-established reliability and validity [14]. It is a 27 item scale, with each item 
rated from 0 – 4, with 4 being “very much” and 0 being “not at all”. Each section was 
scored according to FACIT criteria and a mark was given out of a total of 108.  
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Data Analysis 
Statistical Package for the Social Sciences (IBM) was used to calculate Spearman’s 
correlation in order to compare mTNS scores with scores for BBS, TUG, and FACT-
G. Descriptive statistics and graphs used to profile mTNS were completed in 
Microsoft Excel and Graphpad Prism.  
 
Results 
 
Figure 1 below represents the recruitment process for this study. 
 
 
A total of 29 patients completed testing. Patients ranged in age from 31 to 74, with a 
median age of 62 years. The median number of chemotherapy cycles completed was 4 
(range 3-6).  
Four patients had previously received lines of neurotoxic chemotherapy. However 
these were all completed at least two years prior to commencement of their current 
regimen. 
 
 
  
 
Pharmacy Lists Reviewed 
(Weekly) 
Inclusion/Exclusion Screen (Medical Charts)    n = 
86 
 
 
Met Criteria – Invitation Letter 
Sent 
n = 37 
 
Excluded   n = 49: 
 
-Pre-existing neuro conditions:  n = 6 
-Chemo on hold/stopped/insufficient  
 cycles given: n = 16 
-Diabetes n = 18 
-Alcoholism n = 7 
-Age ˃75 n = 2 
 
Unwell / Chemotherapy Postponed  
n= 5 
 
 
Declined 
n = 3 
Agreed - Included in Study 
n = 29 
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Table 1 Patient characteristics and chemotherapy type 
Chemotherapy 
Class 
Taxanes 
(n=9) 
Platinums 
(n=13) 
Taxane & 
Platinum 
(n=4) 
Vinca-Alkaloid 
(n=3) 
Median Age 47 (range 31-
63) 
65 (range 44-74) 65.5 (range 47-
72) 
74 (range 47-
74) 
Male: Female 1:8 8:5 0:4 0:3 
Type of Cancer 7 Primary 
Breast 
1 Metastatic 
Breast 
1 Metastatic 
Testicular 
3 Primary 
Colorectal 
2 Metastatic 
Colorectal 
4 Primary Lung 
2 Primary 
Oesophogeal 
1 Metastatic 
Breast 
1 Primary 
Gastric 
4 Primary 
Ovarian 
2 Non-Hodgkins 
lymphoma 
 
1 Metastatic 
Breast 
Median no. of 
cycles 
3 (range 3-6) 4 (range3-6) 3.5 (range 3-5) 3 (range 3-3) 
Median mTNS 
score 
5 (range 1-6) 4 (range 1-6) 5.5 (range 4-7) 5 (range 2-12) 
 
Median mTNS score was 5, with a range of 1-12. Using severity levels described 
above, 28 patients would be classified as having a mild neuropathy, and 1 as 
moderate. Notably no patient had an mTNS score of zero. 
 
There were no significant correlations found between mTNS and BERG (r = -.29, p 
=.13), TUG (r = .14, p = .48), or FACT-G (r = 0.05, p = .8). Figures 2 to 4 below 
show the relationship between mTNS and BERG, TUG and FACT –G scores 
respectively 
 
A BBS score below 35 is accepted as indicating a 100% risk of falls, while a score of 
<45 indicates balance impairment, and a score of <40 indicates a need for a balance 
retraining program [15]. In the current sample, the median BBS score was 55 (range 
40-56). No patient scored below 40, and only one patient scored below 45, indicating 
that only one patient in this sample showed signs of balance impairment. This patient 
also had the highest mTNS score (12) and TUG score (15.91). 
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Fig. 2 Scatter plot illustrating association between mTNS and BBS scores 
 
 
 
There are established normal values for TUG: 0-10 seconds: independent/normal, 10-
20 seconds: independent with basic mobility, transfers and stairs, 20-29 seconds: 
variance in gait speed, balance and functional capacity, and ≥30 seconds: need help 
with mobility, transfers & stairs, further assessment warranted [16]. According to our 
data, 19 patients had scores <10 seconds, and 10 patients had scores between 10-20 
seconds, indicating that function in this cohort was not severely impaired. 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Scatterplot illustrating association between mTNS and TUG scores 
 
(r = -.29, p =.13) 
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Normative data exists for the USA for FACT-G. The mean normal total score for the 
FACT-G amongst a sample of 1075 men and women was 80.1 [14]. The mean in the 
current sample was 80.5, only slightly higher than that of a normal sample. Median 
score was 80, with a range of 41-107. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Scatterplot illustrating association between mTNS and FACT-G scores 
 
(r = .14, p = .48) 
 
(r = .14, p = .48) 
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Discussion 
 
This study has provided a profile of CIPN in a cohort of patients treated with 
neurotoxic chemotherapy regimens. It is of interest that all patients had clinical 
evidence of CIPN on mTNS, with a majority having mild levels of neuropathy. 
 
This sample included patients up to 74 years of age. Although advanced age is a risk 
factor for neuropathy, these patients were screened for such underlying neuropathy. It 
has previously been shown that advanced age is not associated with greater risk of 
developing neuropathy as a result of neurotoxic agents, or with more severe CIPN 
should it develop [17] 
 
There were no correlations between mTNS scores and BERG, TUG, or FACT-G. 
This was in contrast with the findings of a study in 2006, which found that the mTNS 
correlated moderately with measures of balance, function, and QoL, including the 
TUG [5]. This study was exclusive to breast cancer patients on taxanes. There were 9 
patients on the current study on taxane regimens, 8 of whom had breast cancer.  Their 
mTNS scores did not correlate with the TUG ( r = -.28, p = .46), BERG ( r=.09, p = 
.83) or FACT-G ( r = .04, p = .91).  
 
(r = 0.05, p = .8) 
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Although this study was sufficiently powered, it would be interesting to look at these 
relationships in a larger sample in order to facilitate statistical analysis of subgroups 
by chemotherapy regimen. Notably however, the abovementioned study [5] had a 
sample size of only 20. It may be the case that because both mTNS scores and 
functional measures showed only mild impairment, this level of impairment was not 
sufficient enough to correlate. It would be interesting to look at the changes in mTNS 
levels and functional outcome measures over the course of chemotherapy and beyond. 
Notably, most of these patients were reviewed in the early stages of their 
chemotherapy treatment.  
 
The functional measures used were chosen because of validity, frequent use in the 
clinical setting, and ease of use. However, it may be that these global tests of balance 
and function may not be specific enough to detect the functional changes associated 
with CIPN. These measures are used widely in ageing populations, and thus may not 
be sensitive enough to detect small changes in function in an otherwise healthy and 
relatively young CIPN population. It is likely that such a cohort may compensate well 
for a sensory deficit, and thus it will not be picked up by global functional measures. 
Future studies could look at measures such as postural sway patterns on a force plate 
or gait variability in a movement laboratory. This would provide more sensitive 
objective detection of smaller changes in gait and balance and capture changes before 
they would be detected by functional outcome measures such as BBS and TUG. 
 
The mTNS proved a sensitive CIPN screening tool, in that it detected even mild levels 
of CIPN, and displayed no floor effect. Although clearly a more objective and 
sensitive tool than global screening tools such as the National Cancer Institute 
Common Toxicity Criteria (NCI-CTC), it is unlikely that the mTNS will be used 
routinely as an alternative to these tools in the clinical setting in light of time and 
training issues. It is however a useful tool for research in this area, and for 
physiotherapy assessment, and could be recommended for clinical use in these two 
areas.  
 
Due to a lack of prospective follow-up studies in this area, there are currently no data 
available as to what score on the mTNS can be considered clinically significant, or 
what increase in mTNS scores would be considered a minimal detectable change in 
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scores over time from baseline to various time points during and after chemotherapy 
treatment. Prospective follow-up studies with multiple time points would give 
information on the natural history of CIPN and inform the interpretation of mTNS 
scores with respect to sensitivity, specificity, and minimal detectable change. This 
information would make the mTNS more clinically relevant, and could aid in the 
decision for dose reduction or treatment cessation. A study in 2007 which looked at 
patients experience of CIPN, found that half of the participants in their study (n=28) 
had not been informed of the possibility of developing CIPN as a side-effect of 
treatment and therefore many of the patients were unaware that they had a neuropathy 
[18]. Currently screening for CIPN relies heavily on subjective descriptions by the 
patient. Patients can be hesitant in reporting any symptoms in fear that their 
chemotherapy dose will be reduced, compromising their treatment [19]. In light of 
this, it may be that neuropathy is currently under-reported and therefore under-
investigated in the clinical setting. 
 
There is a dearth of research into CIPN itself, the use of comprehensive and clinically 
relevant screening tools such as the mTNS, and the relationships between CIPN and 
function. This study has added to the research in these areas. Future research is 
needed specifically to comprehensively validate the mTNS in this population, and to 
examine longitudinally the relationships between CIPN and function and quality of 
life. There is also work to be done in establishing normal values and minimally 
detectable change for the mTNS. 
 
Conclusions 
 
This study provided a profile of CIPN in patients being treated with neurotoxic 
chemotherapy. All patients had clinical evidence of neuropathy on mTNS, indicating 
a high prevalence of CIPN in patients with no other risk factors for peripheral 
neuropathy, who are treated with a neurotoxic chemotherapy regimen. The mTNS 
provided a clinically applicable, sensitive screening tool for CIPN. mTNS did not 
correlate with BERG, TUG or FACT-G in this sample. This may have been due to 
relatively mild levels of CIPN and functional impairments. Future studies should 
validate the mTNS, and prospective follow-up studies with multiple time points are 
warranted to investigate the natural history of CIPN and inform the interpretation of 
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mTNS scores with respect to sensitivity, specificity, and minimal detectable change. 
Studies examining the relationships between CIPN and function should use more 
sensitive measures to detect subtle changes in balance and gait over the course of 
chemotherapy treatment. 
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